Malaria: On a mission to block transmission
The controlled infection of volunteers with Plasmodium falciparum parasites could provide a platform to evaluate new drugs and vaccines aimed at blocking malaria transmission.
- Swiss Tropical and Public Health Institute, Switzerland
- University of Basel, Switzerland
Life inside a human host is fraught with danger. Plasmodium falciparum malaria parasites need to be highly adapted to compete for resources and to take their chances with the immune system. The same degree of specialization is needed to survive inside the mosquito, and for the transitions from human to mosquito and vice versa. These seemingly incompatible needs are met by a life cycle that involves morphing into a series of different forms.
Under the microscope, a blood sample may reveal different stages of the parasite: asexual parasites that replicate and prolong the infection, and sexual stages called gametocytes, the form that transmits the infection from human to mosquito. Both male and female gametocytes arise when a small proportion of asexual parasites stop replication and commit to sexual development instead. After maturation they are either taken up by a feeding mosquito or die. Sex and transmission are inextricably linked. Fertilization occurs inside the mosquito gut within an hour of feeding and leads to several developmental phases inside the insect vector, after which parasites are ready to infect a new human host (Sinden, 2017).
Most licensed antimalarial drugs target the asexual forms of the parasite. These stages are the most abundant and cause the symptoms of malaria (Sinden, 2017; Nilsson et al., 2015). As the burden of disease has declined in many regions and the focus is shifting towards malaria elimination, the searchlight beam now falls onto other stages. On paper, gametocytes are a good target to break the circle of transmission: they are the only form capable of infecting mosquitoes and their low number creates a population bottleneck.
However, efforts to introduce new drugs and vaccines that target gametocytes and prevent malaria transmission face an obstacle: there is no method to directly evaluate their success in humans. Clinical studies in malaria patients can demonstrate the effect of drugs on asexual parasites, but often fail to capture the dynamics of gametocytes for simple reasons. Gametocytes generally occur at very low densities and are often missed by standard detection methods. They sequester away from the blood stream for eight to twelve days as they mature, and often are not seen at the time of illness. Consequently, the evaluation of drugs is mostly limited to unnatural conditions, such as measuring gametocyte densities in cell cultures or artificially feeding blood infected with gametocytes to mosquitoes.
Now, in eLife, Robert Sauerwein, Teun Bousema and colleagues – including Isaie Reuling as first author – report a promising method to fill this void (Reuling et al., 2018). The researchers – who are based at the Radboud University Medical Center and other universities and non-profit organizations in the UK, United States, Australia and the Netherlands – drew on recent scientific developments in sensitive molecular diagnostic methods, the stage-specificity of drugs and the resurgence of interest in human challenge studies (Farid et al., 2017; Stanisic et al., 2018; Stone et al., 2017).
Reuling et al. deliberately infected volunteers with P. falciparum using Anopheles mosquitoes. The ensuing asexual parasite densities were controlled and eventually cleared using different drugs while allowing the gametocytes to continue development under safe conditions. All of the volunteers yielded circulating gametocytes.
A crucial question is how well this method of generating gametocytes in humans would work to evaluate a compound that blocks transmission. Effects on gametocyte densities can be shown (Collins et al., 2018). However, such densities are only loosely related to transmission success (Churcher et al., 2013). The most relevant measure would be whether or not feeding mosquitoes become infected. Reuling et al. observed that the low gametocyte numbers in the volunteers only sporadically infected mosquitoes, and are aware that this renders conclusions about transmission-blocking activity impossible.
Changing certain elements of the study setup, for example using different drugs, treatment doses, P. falciparum laboratory strains or mosquito species, may overcome this issue. Another possibility could be to enhance gametocyte production by inducing sexual commitment. However, we are only beginning to understand the triggers for this process (Bechtsi and Waters, 2017). Recently, a human lipid was shown to inhibit sexual commitment (Brancucci et al., 2017). Interfering with the underlying regulatory pathway could be exploited in the future. But regardless of how these problems are tackled, questions of how well the system translates into real life settings would need to be addressed carefully.
A side-effect of piloting the method of controlled human infection is the insight into the secret lives of gametocytes. Previously, the most detailed studies of gametocyte dynamics had been made when deliberate infections were used to treat neurosyphilis patients at a time before antibiotics were available (Snounou and Pérignon, 2013). By using highly sensitive and sex-specific detection methods, Reuling et al. add to the pool of knowledge and provide evidence that mature male and female gametocytes first appear in the blood at different times, and that female gametocytes circulate in the blood for longer. The early appearance of mature gametocytes in the peripheral blood of the volunteers further suggests that a fraction of the first wave of parasites entering the blood stream can already be sexually committed.
A system to evaluate potential transmission-blocking strategies in vivo is hugely appealing. In future, an optimized setup that can achieve a higher proportion of infected mosquitoes may help to discover new ways to prevent malaria transmission. The work of Reuling et al. has opened a door.
Figure 1
Red blood cells infected with Plasmodium falciparum parasites.
Malaria parasites have a complex life cycle and different forms of the parasites can be found in the blood. This scanning electron micrograph shows red blood cells infected with the parasite: an asexual stage on the left and a mature gametocyte on the right. Only the gametocytes can infect mosquitoes.
© Brand, 2018. Image courtesy of Françoise Brand, Swiss Tropical and Public Health Institute and University of Basel. Published under a CC BY 4.0 license.
References
-
Genomics and epigenetics of sexual commitment in PlasmodiumInternational Journal for Parasitology 47:425–434.https://doi.org/10.1016/j.ijpara.2017.03.002
-
A controlled human malaria infection model enabling evaluation of transmission-blocking interventionsJournal of Clinical Investigation 98012.https://doi.org/10.1172/JCI98012
-
Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infectionThe Journal of Infectious Diseases 215:1167–1174.https://doi.org/10.1093/infdis/jix035
-
Targeting human transmission biology for malaria eliminationPLoS Pathogens 11:e1004871.https://doi.org/10.1371/journal.ppat.1004871
-
Malariotherapy--insanity at the service of malariologyAdvances in Parasitology 81:223–255.https://doi.org/10.1016/B978-0-12-407826-0.00006-0
-
Controlled human malaria infection: applications, advances, and challengesInfection and Immunity 86:e00479-17.https://doi.org/10.1128/IAI.00479-17
Article and author information
Author details
Nicolas MB Brancucci
Acknowledgements
The authors thank Eilidh Carrington, Natalie Hofmann, Melissa Penny, Matthias Rottmann, Tom Smith and Till Voss for helpful discussions.
Publication history
- Version of Record published: February 27, 2018 (version 1)
Copyright
© 2018, Ross et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,308
- views
-
- 446
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Malaria: On a mission to block transmission
eLife 7:e35246.
https://doi.org/10.7554/eLife.35246
Further reading
-
- Microbiology and Infectious Disease
Survival of Mycobacterium tuberculosis within the host macrophages requires the bacterial virulence regulator PhoP, but the underlying reason remains unknown. 3′,5′-Cyclic adenosine monophosphate (cAMP) is one of the most widely used second messengers, which impacts a wide range of cellular responses in microbial pathogens including M. tuberculosis. Herein, we hypothesized that intra-bacterial cAMP level could be controlled by PhoP since this major regulator plays a key role in bacterial responses against numerous stress conditions. A transcriptomic analysis reveals that PhoP functions as a repressor of cAMP-specific phosphodiesterase (PDE) Rv0805, which hydrolyzes cAMP. In keeping with these results, we find specific recruitment of the regulator within the promoter region of rv0805 PDE, and absence of phoP or ectopic expression of rv0805 independently accounts for elevated PDE synthesis, leading to the depletion of intra-bacterial cAMP level. Thus, genetic manipulation to inactivate PhoP-rv0805-cAMP pathway decreases cAMP level, stress tolerance, and intracellular survival of the bacillus.
-
- Biochemistry and Chemical Biology
- Microbiology and Infectious Disease
To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.
